Endocyte, Inc.
ENDOCYTE INC (Form: 8-K, Received: 06/21/2011 16:14:50)  

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   June 15, 2011

Endocyte, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 001-35050 35-1969-140
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana   47906
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   765-463-7175

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 15, 2011, Endocyte, Inc. (the "Company") announced that it had appointed Binh Nguyen, M.D., Ph.D., as Vice President of Clinical Affairs, succeeding to the responsibilities previously performed by Richard Messmann, M.D., one of the Company's "named executive officers". Dr. Messmann's employment with the Company is expected to terminate effective July 22, 2011, and will entitle him, under his Change in Control and Severance Agreement, to receive the severance benefits applicable to a termination of employment without cause or by the executive with good reason occurring prior to a change in control transaction.

A copy of the Company’s press release announcing these events is attached as Exhibit 99.1 to this report and the information in the press release is incorporated by reference into this report.





Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 Press release dated June 15, 2011






Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Endocyte, Inc.
          
June 21, 2011   By:   /s/ Michael A. Sherman
       
        Name: Michael A. Sherman
        Title: Chief Financial Officer


Top of the Form

Exhibit Index


     
Exhibit No.   Description

 
99.1
  Press release dated June 15, 2011

Exhibit 99.1
Contacts:

Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200
Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292
Tony Russo, Ph. D., Russo Partners, (212) 845 4251

FOR IMMEDIATE RELEASE:

Endocyte Names Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs

WEST LAFAYETTE, Ind., June 15, 2011 Endocyte, Inc ., (NASDAQ: ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced the appointment of Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs. He succeeds Richard Messmann, M.D., Endocyte’s Vice President of Medical Affairs since 2005.

“We are excited to welcome Binh to our team. His track record of product approval success will be of great value to Endocyte as we focus on moving our lead product candidate and companion imaging diagnostic toward the market,” said Ron Ellis, Endocyte’s President and CEO. “We would also like to acknowledge Rich for his contributions in helping the company reach its current stage, with its first product approval regulatory filings in sight.”

Dr. Nguyen has more than 20 years of experience in clinical drug development. He was previously Chief Medical Officer at Tigris Pharmaceuticals. Prior to this, he worked at Eli Lilly for 10 years, most recently as Executive Director, Global Oncology Platform Team, for which he was responsible for the global development of Gemzar®, Alimta®, and Enzastaurin. Dr. Nguyen’s work contributed to the global approvals of Alimta® and Gemzar® in six indications: mesothelioma, first and second-line non-small cell lung cancer, as well as pancreatic, bladder, breast and ovarian cancers.

Dr. Nguyen received his Ph.D. in organic chemistry from Georgetown University and his M.D. from the University of Maryland. He completed fellowships at the National Cancer Institute and worked at the FDA’s Division of Oncology as a medical reviewer.

About Endocyte
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.